Wedbush Upgrades Harpoon Therapeutics (HARP) to Outperform

Wedbush analyst Robert Driscoll upgraded Harpoon Therapeutics (NASDAQ: HARP) from Neutral to Outperform with a price target of $7.00 (from $5.00).

For an analyst ratings summary and ratings history on Harpoon Therapeutics click here. For more ratings news on Harpoon Therapeutics click here.

Shares of Harpoon Therapeutics closed at $2.00 yesterday.

You May Also Be Interested In

• Freedom Broker Upgrades Morgan Stanley (MS) to Buy
• Permian Resources Corp (PR) PT Lowered to $24 at UBS Ahead of Q2 Earnings
• Green Plains Renewable Energy (GPRE) PT Raised to $20 at UBS Ahead of Q2 Results